Is Eli Lilly Stock a Good Investment?

Eli Lilly Investment Advice

  LLY
To provide specific investment advice or recommendations on Eli Lilly and stock, we recommend investors consider the following general factors when evaluating Eli Lilly and. This will help you to make an informed decision on whether to include Eli Lilly in one of your diversified portfolios:
  • Examine Eli Lilly's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Eli Lilly's leadership team and their track record. Good management can help Eli Lilly navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Eli Lilly's business and its evolving consumer preferences.
  • Compare Eli Lilly's performance and market position to its competitors. Analyze how Eli Lilly is positioned in terms of product offerings, innovation, and market share.
  • Check if Eli Lilly pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Eli Lilly's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Eli Lilly and stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Eli Lilly and is a good investment.
 
Sell
 
Buy
Strong Buy
Macroaxis provides advice on Eli Lilly to complement and cross-verify current analyst consensus on Eli Lilly and. Our investment recommendation engine determines the company's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon. To make sure Eli Lilly is not overpriced, please confirm all Eli Lilly fundamentals, including its price to book, cash flow from operations, current liabilities, as well as the relationship between the cash and equivalents and beta . Given that Eli Lilly has a price to earning of 54.92 X, we urge you to verify Eli Lilly and market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Market Performance

GoodDetails

Volatility

Very steadyDetails

Hype Condition

Over hypedDetails

Current Valuation

Fairly ValuedDetails

Odds Of Distress

Very LowDetails

Economic Sensitivity

Follows the market closelyDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

HealthyDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Possible ManipulatorDetails

Examine Eli Lilly Stock

Researching Eli Lilly's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 84.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.43. Eli Lilly recorded earning per share (EPS) of 5.82. The entity last dividend was issued on the 14th of February 2024. The firm had 2:1 split on the 16th of October 1997.
To determine if Eli Lilly is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eli Lilly's research are outlined below:
Over 84.0% of the company shares are owned by institutional investors
On 8th of March 2024 Eli Lilly paid $ 1.3 per share dividend to its current shareholders
Latest headline from stockhead.com.au: Acquisition by Ralph Alvarez of tradable shares of Eli Lilly at 750.77 subject to Rule 16b-3

Eli Lilly Quarterly Accounts Payable

2.6 Billion

Eli Lilly uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eli Lilly and. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eli Lilly's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View
Earnings surprises can significantly impact Eli Lilly's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Eli Lilly's investors have experienced.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
1996-10-22
1996-09-300.320.380.0618 
2015-04-23
2015-03-310.770.870.112 
2015-10-22
2015-09-300.760.890.1317 
2012-04-25
2012-03-310.780.920.1417 
2010-07-22
2010-06-301.11.240.1412 
2015-07-23
2015-06-300.740.90.1621 
2013-07-24
2013-06-3011.160.1616 
2009-10-21
2009-09-301.021.20.1817 

Know Eli Lilly's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Eli Lilly is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eli Lilly and backward and forwards among themselves. Eli Lilly's institutional investor refers to the entity that pools money to purchase Eli Lilly's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2023-12-31
16 M
Morgan Stanley - Brokerage Accounts2023-12-31
12.7 M
Wellington Management Company Llp2023-12-31
11.8 M
Norges Bank2023-12-31
10.3 M
Bank Of America Corp2023-12-31
9.9 M
Goldman Sachs Group Inc2023-12-31
9.4 M
Northern Trust Corp2023-12-31
9.1 M
Jennison Associates Llc2023-12-31
7.6 M
Capital Research Global Investors2023-12-31
7.6 M
Lilly Endowment Inc2023-12-31
99.8 M
Vanguard Group Inc2023-12-31
71.6 M
Note, although Eli Lilly's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Eli Lilly's market capitalization trends

The company currently falls under 'Mega-Cap' category with a total capitalization of 713.81 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eli Lilly's market, we take the total number of its shares issued and multiply it by Eli Lilly's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Market Cap

495.87 Billion

Eli Lilly's profitablity analysis

Eli Lilly's profitability indicators refer to fundamental financial ratios that showcase Eli Lilly's ability to generate income relative to its revenue or operating costs. If, let's say, Eli Lilly is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Eli Lilly's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Eli Lilly's profitability requires more research than a typical breakdown of Eli Lilly's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.10  0.14 
Return On Capital Employed 0.28  0.25 
Return On Assets 0.08  0.12 
Return On Equity 0.49  0.26 
The company has Net Profit Margin of 0.15 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.34 %, which entails that for every 100 dollars of revenue, it generated $0.34 of operating income.
Determining Eli Lilly's profitability involves analyzing its financial statements and using various financial metrics to determine if Eli Lilly is a good buy. For example, gross profit margin measures Eli Lilly's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eli Lilly's profitability and make more informed investment decisions.
The data published in Eli Lilly's official financial statements usually reflect Eli Lilly's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Eli Lilly. For example, before you start analyzing numbers published by Eli accountants, it's critical to develop an understanding of what Eli Lilly's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Eli Lilly's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eli Lilly's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Eli Lilly's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eli Lilly and. Please utilize our Beneish M Score to check the likelihood of Eli Lilly's management manipulating its earnings.

Evaluate Eli Lilly's management efficiency

Eli Lilly has Return on Asset of 0.1188 % which means that on every $100 spent on assets, it made $0.1188 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4844 %, implying that it generated $0.4844 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eli Lilly's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.25 in 2024. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 40.2 B in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 2.9 B in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 11.97  6.16 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share(1.09)(1.04)
Enterprise Value Over EBITDA 43.93  46.12 
Price Book Value Ratio 48.71  51.15 
Enterprise Value Multiple 43.93  46.12 
Price Fair Value 48.71  51.15 
Enterprise Value492.4 B517 B
The analysis of Eli Lilly's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Eli Lilly's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Eli Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Dividend Yield
0.007
Forward Dividend Yield
0.007
Forward Dividend Rate
5.2
Beta
0.367

Basic technical analysis of Eli Stock

As of the 17th of April 2024, Eli Lilly shows the Mean Deviation of 1.16, downside deviation of 1.46, and Coefficient Of Variation of 624.13. In respect to fundamental indicators, the technical analysis model provides you with a way to check existing technical drivers of Eli Lilly, as well as the relationship between them. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Eli Lilly and, which can be compared to its peers. Please confirm Eli Lilly downside deviation, treynor ratio, as well as the relationship between the Treynor Ratio and expected short fall to decide if Eli Lilly is priced favorably, providing market reflects its regular price of 746.74 per share. Given that Eli Lilly has jensen alpha of 0.2138, we urge you to verify Eli Lilly and's prevailing market performance to make sure the company can sustain itself at a future point.

Eli Lilly's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eli Lilly insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eli Lilly's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eli Lilly insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Eli Lilly's Outstanding Corporate Bonds

Eli Lilly issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Eli Lilly uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Eli bonds can be classified according to their maturity, which is the date when Eli Lilly and has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Understand Eli Lilly's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Eli Lilly's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider Eli Lilly's intraday indicators

Eli Lilly intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Eli Lilly stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Eli Lilly Corporate Filings

F4
16th of April 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
11th of April 2024
Other Reports
ViewVerify
22nd of March 2024
Other Reports
ViewVerify
8th of March 2024
Other Reports
ViewVerify
Eli Lilly time-series forecasting models is one of many Eli Lilly's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Eli Lilly's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Eli Stock media impact

Far too much social signal, news, headlines, and media speculation about Eli Lilly that are available to investors today. That information is available publicly through Eli media outlets and privately through word of mouth or via Eli internal channels. However, regardless of the origin, that massive amount of Eli data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eli Lilly news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eli Lilly relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eli Lilly's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eli Lilly alpha.

Eli Lilly Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Eli Lilly can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Eli Lilly Historical Investor Sentiment

Investor biases related to Eli Lilly's public news can be used to forecast risks associated with an investment in Eli. The trend in average sentiment can be used to explain how an investor holding Eli can time the market purely based on public headlines and social activities around Eli Lilly and. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Eli Lilly's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Eli Lilly and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Eli Lilly news discussions. The higher the estimate score, the more favorable the investor's outlook on Eli Lilly.

Eli Lilly Maximum Pain Price across 2024-04-19 Option Contracts

Eli Lilly's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Eli Lilly close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Eli Lilly's options.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Eli Lilly without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sectors Now

   

Sectors

List of equity sectors categorizing publicly traded companies based on their primary business activities
All  Next Launch Module

Eli Lilly Corporate Directors

Eli Lilly corporate directors refer to members of an Eli Lilly board of directors. The board of directors generally takes responsibility for the Eli Lilly's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Eli Lilly's board members must vote for the resolution. The Eli Lilly board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Ralph AlvarezIndependent DirectorProfile
Jamere JacksonIndependent DirectorProfile
Juan LucianoLead Independent DirectorProfile
Karen WalkerIndependent DirectorProfile

How to buy Eli Stock?

To provide specific investment advice or recommendations on Eli Lilly and stock, we recommend investors consider the following general factors when evaluating Eli Lilly and. This will help you to make an informed decision on whether to include Eli Lilly in one of your diversified portfolios:
  • Examine Eli Lilly's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Eli Lilly's leadership team and their track record. Good management can help Eli Lilly navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Eli Lilly's business and its evolving consumer preferences.
  • Compare Eli Lilly's performance and market position to its competitors. Analyze how Eli Lilly is positioned in terms of product offerings, innovation, and market share.
  • Check if Eli Lilly pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Eli Lilly's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Eli Lilly and stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Eli Lilly and is a good investment.

Already Invested in Eli Lilly and?

The danger of trading Eli Lilly and is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Eli Lilly is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Eli Lilly. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Eli Lilly is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.13
Dividend Share
4.52
Earnings Share
5.82
Revenue Per Share
37.908
Quarterly Revenue Growth
0.281
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Eli Lilly's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.